Ro; Seonggu

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ro; Seonggu.The latest application filed is for "2,3-dihydro-isoindole-1-one derivative as btk kinase suppressant, and pharmaceutical composition including same".

Company Profile

2.6.11

Ro; Seonggu - Seoul KR
Ro; Seonggu - Gyeonggi-do KR
Ro; Seonggu - Daejeon KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same Grant 11,230,539 - Hong , et al. January 25, 2	2022-01-25
2,3-dihydro-isoindole-1-one Derivative As Btk Kinase Suppressant, And Pharmaceutical Composition Including Same App 20210009565 - HONG; Yong Rae ; et al.	2021-01-14
2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same Grant 10,604,508 - Hong , et al.	2020-03-31
Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability Grant 10,413,520 - Kim , et al. Sept	2019-09-17
Oral Pharmacological Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone Having Crystalline Structure With Excellent Stability App 20180008571 - KIM; Byung-Ha ; et al.	2018-01-11
2,3-dihydro-isoindole-1-one Derivative As Btk Kinase Suppressant, And Pharmaceutical Composition Including Same App 20170362205 - Hong; Yong Rae ; et al.	2017-12-21
2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same Grant 9,758,508 - Hong , et al. September 12, 2	2017-09-12
Pharmaceutical Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone And Capsule Formulation Including The Pharmaceutical Composition App 20170000759 - KIM; Byung-Ha ; et al.	2017-01-05
2,3-dihydro-isoindole-1-on Derivative As Btk Kinase Suppressant, And Pharmaceutical Composition Including Same App 20150336934 - HONG; Yong Rae ; et al.	2015-11-26
Fab I inhibitor and process for preparing same Grant 7,973,060 - Kim , et al. July 5, 2	2011-07-05
Pyridine Derivatives And Methods Of Use Thereof App 20110028507 - Kim; Sun Nam ; et al.	2011-02-03
2-aminoquinazoline Derivative App 20100311965 - Sawa; Masaaki ; et al.	2010-12-09
Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same App 20090170847 - Lee; Seung Chul ; et al.	2009-07-02
Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same App 20070254882 - Cho; Joong Myung ; et al.	2007-11-01
Fab I Inhibitor and Process for Preparing Same App 20070135465 - Kim; Cheol Min ; et al.	2007-06-14
Glycogen synthase kinase 3.beta. inhibitor, composition and process for the preparation thereof Grant 7,179,832 - Cho , et al. February 20, 2	2007-02-20
Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof App 20060079521 - Cho; Joong Myung ; et al.	2006-04-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.